AT
Athira Pharma, Inc.
ATHA · NASDAQ
$6.75 -6.12% (-$0.44)
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
1/9Valuation
-
N/A P/FCF N/A
P/S N/A
P/B N/A
Growth
-
N/A Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
-
N/A ROE N/A
ROA N/A
Asset turnover N/A
Debt
-
N/A Debt/Assets N/A
Int. coverage N/A
Net debt/EBITDA N/A
Stability
0 /100
Unstable Beta 2.80x
EPS volatility N/A
Profitable years N/A
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ATHA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Mark J. Litton
Employees
26
Headquarters
Bothell